



# BAISHIDENG PUBLISHING GROUP INC

7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 33308

**Title:** Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer

**Reviewer's code:** 00292853

**Reviewer's country:** Germany

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2017-02-07

**Date reviewed:** 2017-02-21

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

### COMMENTS TO AUTHORS

The study aimed to evaluate whether there was a differential treatment effect according to histology in three randomised phase III studies with advanced oesophageal SCC and adenocarcinoma. While there was no significant difference in survival between patients with adenocarcinoma and SCC, the overall response rate to chemotherapy was different. Thus, the authors conclude that SCC-specific trials in advanced oesophageal cancer are needed. In the Introduction section: ramucirumab is an antibody targeting VEGFR2 and not VEGF. This needs to be corrected.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 33308

**Title:** Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer

**Reviewer's code:** 01806391

**Reviewer's country:** Spain

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2017-02-28

**Date reviewed:** 2017-03-07

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

### COMMENTS TO AUTHORS

In this study the authors have evaluated whether the response to first-line chemotherapy was different in patients with advanced oesophageal depending on whether the tumour histological subtype was adenocarcinoma and squamous cell carcinoma (SCC). The results revealed slightly worse outcome for SCC, although the authors have concluded that there is no significant difference between both subtypes. The study is interesting and relevant. I have some comments to improve the manuscript. 1. The title must be refined. Rather than "histology" the impact should refer to "the histological subtype of tumour". 2. In addition, the title is misleading. It should show that the conclusion is negative (for instance: "Absence of impact...") or leave the question open (for instance: "Is there an impact...?"), but as it is now, the title suggests the existence of such impact.